Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant
暂无分享,去创建一个
A. Bednarska | R. Flisiak | J. Jaroszewicz | P. Czupryna | P. Rzymski | A. Piekarska | K. Sikorska | M. Rogalska | D. Zarębska-Michaluk | D. Kozielewicz | M. Rorat | A. Moniuszko-Malinowska | K. Dobrowolska | Justyna Anna Kryńska | Anna M. Moniuszko-Malinowska | Anna M Moniuszko-Malinowska | Krystyna Dobrowolska
[1] J. Haughney,et al. Directions of change in intrinsic case severity across successive SARS-CoV-2 variant waves have been inconsistent , 2023, The Journal of infection.
[2] E. Nicastri,et al. Evolution of SARS‐CoV‐2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID‐19 in an Italian reference hospital: Impact on clinical outcomes , 2023, Journal of medical virology.
[3] S. Madhi,et al. SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines , 2023, Frontiers in Immunology.
[4] A. Zoufaly,et al. A retrospective analysis of clinical features of patients hospitalized with SARS-CoV-2 Omicron variants BA.1 and BA.2 , 2023, Scientific reports.
[5] Xiawei Wei,et al. The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants , 2023, MedComm.
[6] Wang-Qin Shen,et al. Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019–positive patients , 2023, Clinical Microbiology and Infection.
[7] Lu Lu,et al. SARS‐CoV‐2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan‐coronavirus fusion inhibitors , 2023, Journal of medical virology.
[8] D. De Cock,et al. Surfing the Waves: Differences in Hospitalised COVID-19 Patients across 4 Variant Waves in a Belgian University Hospital , 2023, Viruses.
[9] Lu Lu,et al. SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors , 2023, Emerging microbes & infections.
[10] Xinbing Sui,et al. Omicron subvariant BA.5 is highly contagious but containable: Successful experience from Macau , 2023, Frontiers in Public Health.
[11] S. Joshi,et al. Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected With Omicron Subvariants and the XBB Recombinant Variant , 2023, medRxiv.
[12] R. Flisiak,et al. Variability in the Clinical Course of COVID-19 in a Retrospective Analysis of a Large Real-World Database , 2023, Viruses.
[13] M. Bhattacharya,et al. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies , 2023, Viruses.
[14] H. Sbihi,et al. Clinical severity of Omicron subvariants BA.1, BA.2, and BA.5 in a population‐based cohort study in British Columbia, Canada , 2022, Journal of medical virology.
[15] L. Danon,et al. Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom , 2022, The Lancet Regional Health - Europe.
[16] M. Kiso,et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB , 2022, The New England journal of medicine.
[17] E. Klein,et al. Omicron Subvariants: Clinical, Laboratory, and Cell Culture Characterization , 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[18] A. Nardone,et al. Global SARS-CoV-2 seroprevalence from January 2020 to April 2022: A systematic review and meta-analysis of standardized population-based studies , 2022, PLoS medicine.
[19] H. Ullum,et al. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark , 2022, The Lancet Infectious Diseases.
[20] Y. Teng,et al. The outbreak of SARS‐CoV‐2 Omicron lineages, immune escape, and vaccine effectivity , 2022, Journal of medical virology.
[21] J. Zahradník,et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5 , 2022, Cell.
[22] H. van Bakel,et al. Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants , 2022, The New England journal of medicine.
[23] R. Flisiak,et al. Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance , 2022, Pharmacological Reports.
[24] M. Mendelson,et al. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa , 2022, International Journal of Infectious Diseases.
[25] A. von Gottberg,et al. Clinical severity of omicron lineage BA.2 infection compared with BA.1 infection in South Africa , 2022, The Lancet.
[26] Jong Hyuk Lee,et al. Chest CT Findings in Hospitalized Patients with SARS-CoV-2: Delta versus Omicron Variants , 2022, Radiology.
[27] F. Gleeson,et al. Reduction in Chest CT Severity and Improved Hospital Outcomes in SARS-CoV-2 Omicron Compared with Delta Variant Infection , 2022, Radiology.
[28] Gheyath K Nasrallah,et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections , 2022, The New England journal of medicine.
[29] Fei Shao,et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.
[30] M. Lipsitch,et al. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California , 2022, Nature Medicine.
[31] M. S. Islam,et al. Is the SARS CoV-2 Omicron Variant Deadlier and More Transmissible Than Delta Variant? , 2022, International journal of environmental research and public health.
[32] K. Simon,et al. Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of February 23, 2022. , 2022, Polish archives of internal medicine.
[33] H. Jacquier,et al. Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments , 2022, Annals of Internal Medicine.
[34] J. Dushoff,et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa , 2022, Science.
[35] M. Exline,et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study , 2022, BMJ.
[36] Gheyath K Nasrallah,et al. Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage , 2022, Nature Communications.
[37] I. Abeyagunawardena,et al. A comparison of transmissibility of SARS-CoV-2 variants of concern , 2022, Virology Journal.
[38] P. Noble,et al. Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance — One Hospital, California, July 15–September 23, 2021, and December 21, 2021–January 27, 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[39] Q. Ye,et al. The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant , 2022, Journal of medical virology.
[40] K. Simon,et al. Management of SARS-CoV- infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of April 26, 2021. , 2021, Polish archives of internal medicine.
[41] P. Cinque,et al. Smell and taste disorders in COVID-19: From pathogenesis to clinical features and outcomes , 2021, Neuroscience Letters.
[42] N. Schröter,et al. Anosmia in COVID-19 patients , 2020, Clinical Microbiology and Infection.
[43] Lei Dong,et al. Kidney disease is associated with in-hospital death of patients with COVID-19 , 2020, Kidney International.